MS drugs may raise risks for pregnancy complications, study finds

A new population study reveals that disease-modifying drugs used to treat multiple sclerosis are linked to adverse pregnancy outcomes. The findings could reshape treatment decisions for women of childbearing age and pressure pharmaceutical companies to expand safety data collection during pregnancy.

Originaltitel: Multiple sclerosis, disease-modifying drugs and risk for adverse perinatal and pregnancy outcomes: Results from a population-based cohort study